Hunterbrook Media issued a report on Hims & Hers this morning and noted that based on its reporting, Hunterbrook Capital is short the stock. Hims & Hers sells knockoff GLP-1 weight loss drugs through a loophole that could end at any time, Hunterbrook’s Sam Koppelman, Matthew Termine and Michelle Cera report. The journalists say Hims & Hers relies on a sole GLP-1 supplier “with previously unreported ties to fraud and bankruptcy. They note that a Hunterbrook Media reporter qualified for GLP-1 knockoffs from Hims after a four-minute survey, then got a prescription without speaking to a doctor or submitting medical records. The company could suffer legal liability if GLP-1 knockoffs prove unsafe, ineffective, or violate a patent, according to an FDA legal expert, adds Hunterbrook. Hims & Hers shares are down 3% to $21 following the report.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims and Hers Health call volume above normal and directionally bullish
- Hims & Hers price target raised to $26 from $22 at BofA
- Hims & Hers price target raised to $22 from $17.25 at BofA
- Unusually active option classes on open May 31st
- Hims & Hers price target raised to $26 from $24 at Seaport Research